Nanobiotix SA said it has announced complete full cohort phase 1 results for JNJ-1900 (NBTXR3) in inoperable, recurrent non-small cell lung cancer.
- Enrollment in the dose-escalation and expansion parts of the study is complete per protocol.
- Following encouraging findings, additional patient enrollment in this study is planned.
- All 24 patients completed JNJ-1900 (NBTXR3) treatment with no dose-limiting toxicities or grade 3+ adverse events.
- Grade 3 radiotherapy-related adverse events were reported in 33%, and grade 5 in 8%; phase 2 dose was set at 33% gross tumor volume.
- Investigators concluded that JNJ-1900 (NBTXR3) may permit clinically meaningful local control using a substantially lower re-irradiation dose.
- At 12-month follow-up (Aug. 2026), one-year locoregional control rate was 79%, local progression-free survival (LPFS) 61%, and overall survival (OS) 70%.
NBTX•
